-
Marken Enhances Presence In China
2/7/2012
Marken announced recently that it has recently received approval for its application for an expanded business license to allow the storage and distribution of clinical trial supplies and drug product in China.
-
‘Smarter Particle Sizing’ On Malvern Booth At Pittcon 2012 Booth #3641
2/7/2012
Materials characterization company Malvern Instruments focuses on ‘smarter particle sizing' as the Mastersizer 3000 laser diffraction particle size analyzer makes its Pittcon debut in 2012 (Booth #3641 Pittcon 2012, 11-15 Mar 2012, Orlando, FL).
-
PTI Non-Destructive Package Integrity Inspection System Will Be Exhibited At IPACK-IMA In Milan, Italy
2/7/2012
PTI Inspection System's agent in Europe, Nordtest SRL, will be exhibiting at the upcoming IPACK-IMA EXHIBITION IN MILAN, ITALY, FEBRUARY 28 – MARCH 3, 2012, IN BOOTH PAD.9 Stand B36B.
-
Drug Delivery Hits It Big In Vegas
2/6/2012
Pharma and biotech experts from around the globe gathered in Las Vegas from January 25 to 27 for Drug Delivery Partnerships 2012 (DDP). Vegas seemed an appropriate location, because drug development is a high stakes game filled with risk and reward.
-
Spraying Systems Co. Releases New Online Catalog For The Pharmaceutical Industry
2/6/2012
Spraying Systems Co. announces the release of Catalog 12, an online catalog outlining the company's entire line of products and capabilities for the pharmaceutical and biologics industries.
-
Eriez' 5-Star Service Provides Regular Equipment Checks With Detailed Reports Via Inspection/Preventive Maintenance Program
2/6/2012
Eriez' 5-Star Service helps eliminate or reduce equipment downtime by ensuring that customers' magnetic, vibratory and inspection processing equipment is quickly back in operation and functioning at peak performance.
-
2011 FDA Biopharmaceutical Approvals: Low Number And Economic Impact, But A Record Number Of Orphan Approvals And Many Innovations
2/3/2012
The latest annual study of FDA biopharmaceutical product approvals by the Biotechnology Information Institute (BII) reports significant advances in health care, particularly approvals for new and orphan indications, but an overall low number of approvals and industry and economic impact.
-
Mylan Receives Tentative FDA Approval For Generic Version Of Lipitor®
2/3/2012
Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited (formerly Matrix Laboratories Limited) has received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Atorvastatin Calcium Tablets, 10 mg (base), 20 mg (base), 40 mg (base) and 80 mg (base).
-
Bayer Initiates Expanded Access Program For Investigational Compound Radium-223 Chloride
2/3/2012
Bayer HealthCare, LLC today announced that the U.S. Food and Drug Administration agreed that Bayer can proceed with its expanded access program to provide the investigational drug radium-223 chloride to patients diagnosed with castration-resistant prostate cancer (CRPC)/hormone-refractory prostate cancer (HRPC) with symptomatic bone metastases.
-
Del Mar Pharmaceuticals Granted U.S. Orphan Drug Designation For VAL-083 For The Treatment Of Glioma
2/3/2012
DelMar Pharma today announced that the United States FDA Office of Orphan Products Development has granted orphan drug designation for VAL-083 for the treatment of glioma, including glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.
